ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    T

    Dr Tara Graff, MD

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

    Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

    POLARIX 5 year efficacy

    Tara Graff, MD
    Hematological Malignancies
    Dr. Tara Graff discusses operationalizing bispecifics into community practice (video 3/3)

    Dr. Tara Graff discusses operationalizing bispecifics into community practice (video 3/3)

    Mosun-operationalizing

    Tara Graff, MD
    Hematological Malignancies
    Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

    Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

    Mosun-SQ data

    Tara Graff, MD
    Hematological Malignancies
    Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).

    Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).

    Mosun-4 year FU

    Tara Graff, MD
    Hematological Malignancies